Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Masaoka-Koga Stage III	NCIT_C112010	[The tumor shows invasion into the neighboring tissues and organs of the lower neck or upper chest.]
Masaoka-Koga Stage IVa	NCIT_C112011	[The tumor shows metastasis throughout the pleural and/or pericardial spaces.]
Masaoka-Koga Stage IV	NCIT_C115034	[The tumor shows metastasis throughout the pleural and/or pericardial spaces or metastasis to distant sites.]
Masaoka-Koga Stage IVb	NCIT_C112012	[The tumor shows lymphogenous or hematogenous metastasis to distant sites.]
Therapeutic Equivalency Study	NCIT_C49665	[A study most often used to compare the efficacy of different formulations to treat a given disease. It is the testing of an old versus a new formulation in healthy volunteers or subjects with the disease under study and usually in one dose.]
Therapeutic Clinical Trial	NCIT_C39536	[A clinical study that involves administering of exposure to the agent/agents to subjects with particular disease to elucidate the most appropriate treatment for a specific medical condition, or to prolong or improve the patient's life.]
Efficacy Study	NCIT_C49666	[A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study.]
Trial Type	NCIT_C49660	[The type of clinical trial performed e.g. efficacy, safety.]
Safety Study	NCIT_C49667	[A study of the relative safety of treatment of a disease. Usually this is a Phase I or II trial.]
Centimeter	NCIT_C49668	[A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.]
Pharmacogenomic Study	NCIT_C49661	[A study of identification and analysis of genomic variations that affect the efficacy of a drug. Pharmacogenomic studies can potentially be predictive of an individual's drug-response or adverse reactions or susceptibility to iatrogenic disorders, and may also reveal new targets that can help in the design of new drugs.]
Human Pharmacology Study	NCIT_C39421	[The Human Pharmacology Study is a clinical study that involves one or more of following activities: assesses tolerance to the agent, defines/describes pharmacokinetics and pharmacodynamics, explores drug metabolism, drugs interactions, and evaluates agent activity. The term usually refers to early clinical stages of drug development.]
Imidazolyl Ethanamide Pentandioic Acid	NCIT_C126647	[An orally bioavailable small molecule, with potential hematopoiesis inducing and antiviral activities. Upon oral administration, myelo001 stimulates the differentiation of bone marrow cells of the leukocytic, lymphocytic, and erythrocytic lineages, and prevents apoptosis of hematopoietic cells. This prevents chemotherapy-induced neutropenia (CIN), inhibits the risk of infections, increases tolerance and allows for the continuation of the neutropenia-inducing chemotherapeutic agent. In addition, myelo 001 has antiviral properties.]
Antiviral Agent	NCIT_C281	[Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.]
Protective Agent	NCIT_C26170	[A class of agents used in prophylactic or curative therapy to attenuate the negative side effects of toxins or drugs. Protective agents belong to various chemical classes, acting through various pharmacological mechanisms. They may neutralize exogenous poisons, coat mucosa for protection against physical or chemical damage, offer antioxidant protection against free radicals or ionizing radiation, or induce endogenous detoxifying enzymes. (NCI04)]
Pharmacodynamic Study	NCIT_C49662	[A study of the biochemical and physiological effect of a drug and the mechanism of drug action and the relationship between drug concentration and effect.]
ALK/FAK/Pyk2 Inhibitor CT-707	NCIT_C126648	[An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, ALK/FAK/Pyk2 inhibitor CT-707 selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.]
ALK Inhibitor	NCIT_C141136	[Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).]
Pharmacokinetic Study	NCIT_C49663	[A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.]
White Carrot	NCIT_C126649	[A vegetable, also known as Arracacha, with potential chemoprevenitve, anti-oxidant and protective activities. White carrot contains a variety of nutrients, including minerals and vitamins. Polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate are mainly responsible for its potential anti-cancer activity.]